Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial

Abstract Aims In the EMPA‐REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease. We evaluated post hoc the degree to which c...

Full description

Bibliographic Details
Main Authors: David Fitchett, Silvio E. Inzucchi, Bernard Zinman, Christoph Wanner, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Anne Pernille Ofstad, Afshin Salsali, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin, Faiez Zannad
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:ESC Heart Failure
Subjects:
Diabetes
Empagliflozin
SGLT2 inhibitor
Heart failure
Mediation analysis
Online Access:https://doi.org/10.1002/ehf2.13615

Internet

https://doi.org/10.1002/ehf2.13615

Similar Items